The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Updated OARSI Guideline for the Non-Surgical Management of Osteoarthritis

Updated OARSI Guideline for the Non-Surgical Management of Osteoarthritis

September 25, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The recently updated Osteoarthritis Research Society International (OARSI) guideline offers comprehensive and patient-centered treatment approaches for individuals with knee, hip and polyarticular osteoarthritis (OA). Raveendhara R. Bannuru, MD, a rheumatologist at Tufts Medical Center, Boston, and colleagues published the guideline online July 3 in Osteoarthritis and Cartilage. The paper also includes a treatment algorithm, which serves as more structured guidance to facilitate individual treatment decisions for patients on a long-term and ongoing basis.1

You Might Also Like
  • Collaborative Guideline Addresses the Perioperative Use of Antirheumatic Drug Therapy
  • New Guideline Recommends Frequent Monitoring & Collaboration for JIA-Associated Uveitis Management
  • Some Placebos More Effective Than Others in Osteoarthritis
Also By This Author
  • Atherosclerosis, Cardiovascular Disease More Common in Patients with Primary Sjögren’s Syndrome

The OARSI voting panel consisted of an international group of experts from a variety of professional backgrounds, including general practice, orthopedic surgery, rheumatology, sports medicine and physiotherapy. The transparent and systematic guideline development process used Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, as well as a well-defined, group-consensus technique. The rigorous GRADE methodology had the advantage of tying evidence quality to the strength of the final recommendations. Evidence quality could be downgraded on the basis of bias risk and the preciseness of estimates. This meant many interventions had a low quality of evidence due to sample size and/or other methodological factors.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In many cases, the panel voted on recommendations based on a combination of indirect evidence and expert opinion. “In contrast to previous OARSI guidelines, we have conducted meta-analyses and quality assessments for each treatment and have provided evidence from all eligible studies along with the sensitivity analyses limiting study quality,” write the authors.

The updated OARSI guideline took a more patient-centered approach than earlier versions. Recommendations are predicated on the distribution of OA within various comorbidity profiles. The guideline also expands on prior reports by including interventions that have not been previously assessed, such as massage, mobilization and manipulation, thermotherapy, taping interventions, electromagnetic therapies and laser therapy. Other interventions included are nerve block therapy, intra-articular platelet-rich plasma, intra-articular stem cell therapy, dextrose prolotherapy, investigational disease-modifying drugs (DMOADs) and a wider range of nutraceutical projects.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The guideline strongly recommends against intra-articular stem cell therapy and therapy with intra-articular, platelet-rich plasma because of the extremely low-quality evidence supporting the treatments, as well as a lack of standardization of the formulations. In contrast, the guideline recommends topical NSAIDs more strongly than all other oral analgesics, due to their favorable balance between consistent efficacy and minor, transient side effects. For the first time, the guideline also includes recommendations for mind-body exercises, such as tai chi and yoga, particularly for patients with knee OA. However, the voting panel held off on recommending FX006, a long-acting extended-release corticosteroid approved by the U.S. Food and Drug Administration. This decision was withheld due to limited evidence from randomized clinical trials.

“Although they do not currently have regulatory approval, we analyzed published data on anti-nerve growth factor treatments for OA and included the evidence tables in the formal voting session,” write the authors. “Anti-[nerve growth factors] showed benefits on pain and functional outcomes in patients with knee and hip OA; they were, however, associated with a higher rate of specific adverse events, such as paresthesia.” Thus, the use of anti-nerve growth factor treatments is not recommended.


Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Jul 3. pii: S1063-4584(19)31116-1. [Epub ahead of print]

Pages: 1 2 | Multi-Page

Filed Under: Conditions, Osteoarthritis Tagged With: guideline, osteoarthritis (OA), Osteoarthritis Research Society International (OARSI)

You Might Also Like:
  • Collaborative Guideline Addresses the Perioperative Use of Antirheumatic Drug Therapy
  • New Guideline Recommends Frequent Monitoring & Collaboration for JIA-Associated Uveitis Management
  • Some Placebos More Effective Than Others in Osteoarthritis
  • New Guideline for the Treatment of Psoriatic Arthritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)